Alx Oncology Holdings Inc (NASDAQ:ALXO)’s traded shares stood at 0.58 million during the last session, with the company’s beta value hitting 0.98. At the close of trading, the stock’s price was $1.74, to imply an increase of 6.75% or $0.11 in intraday trading. The ALXO share’s 52-week high remains $17.83, putting it -924.71% down since that peak but still an impressive 31.61% since price per share fell to its 52-week low of $1.19. The company has a valuation of $91.77M, with an average of 0.75 million shares in intraday trading volume over the past 10 days and average of 1.02 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Alx Oncology Holdings Inc (ALXO), translating to a mean rating of 1.86. Of 5 analyst(s) looking at the stock, 0 analyst(s) give ALXO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.39.
Alx Oncology Holdings Inc (NASDAQ:ALXO) trade information
After registering a 6.75% upside in the last session, Alx Oncology Holdings Inc (ALXO) has traded red over the past five days. The 5-day price performance for the stock is -1.69%, and 12.99% over 30 days. With these gigs, the year-to-date price performance is 4.19%. Short interest in Alx Oncology Holdings Inc (NASDAQ:ALXO) saw shorts transact 7.6 million shares and set a 5.41 days time to cover.
The extremes give us $14 and $38 for target low and target high price respectively. As such, ALXO has been trading -2083.91% off suggested target high and -704.6% from its likely low.
Alx Oncology Holdings Inc (ALXO) estimates and forecasts
Looking at statistics comparing Alx Oncology Holdings Inc share performance against respective industry, we note that the company has outperformed competitors. Alx Oncology Holdings Inc (ALXO) shares are -73.68% down over the last 6 months, with its year-to-date growth rate higher than industry average at 26.20% against 16.60%.
ALXO Dividends
Alx Oncology Holdings Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Alx Oncology Holdings Inc (NASDAQ:ALXO)’s Major holders
Alx Oncology Holdings Inc insiders hold 1.97% of total outstanding shares, with institutional holders owning 94.71% of the shares at 96.61% float percentage. In total, 94.71% institutions holds shares in the company, led by VENBIO PARTNERS LLC. As of 2024-06-30, the company held over 9.7 million shares (or 19.3531% of shares), all amounting to roughly $58.49 million.
The next major institution holding the largest number of shares is FMR LLC with 7.81 million shares, or about 15.5923% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $47.12 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Alx Oncology Holdings Inc (ALXO) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 984.59 shares. This is just over 1.87% of the total shares, with a market valuation of $1.71 million. Data from the same date shows that the other fund manager holds a little less at 867.2, or 1.64% of the shares, all valued at about 1.51 million.
